FDA Splits Blood Irradiators into Approval Tiers
Published Date: 3/18/2026
Proposed Rule
Summary
The FDA is proposing new rules to make blood irradiators safer and more reliable. Devices that stop a serious transfusion problem will need a simpler review, while those aimed at preventing cancer spread will face a tougher approval process. If you make or use these devices, get ready to comment by May 18, 2026, and expect some extra costs for the stricter reviews.
Analyzed Economic Effects
4 provisions identified: 1 benefits, 2 costs, 1 mixed.
Metastasis Irradiators Require PMA
If you make blood irradiators intended to irradiate intraoperatively salvaged blood to prevent metastasis, the FDA proposes to classify those devices as Class III and to require filing a premarket approval (PMA) application. FDA is also issuing a proposed order requiring PMA filing for these devices, which means manufacturers must submit PMAs to seek marketing authorization.
TA-GVHD Irradiators Moved to Class II
If you make blood irradiators intended to prevent transfusion-associated graft-versus-host disease (TA-GVHD), the FDA proposes to classify those devices as Class II (special controls) and require premarket notification (510(k)). The rule would establish special controls (performance testing, labeling, and quality controls) that manufacturers must meet before marketing these prescription devices.
Option to Use Predetermined Change Plans
Manufacturers may use Predetermined Change Control Plans (PCCPs) to implement future device modifications without submitting a new 510(k) or PMA supplement if the changes are consistent with an FDA-approved or cleared PCCP. The proposal references section 515C of the FD&C Act (added by FDORA) as the legal basis for PCCPs.
Estimated Industry Costs and Benefits
FDA estimates that annualized benefits over 10 years would range from $84 to $180,268 at a 7% discount rate (primary estimate $90,176), and from $86 to $184,271 at a 3% discount rate (primary estimate $92,178). Annualized costs are estimated to range from $0.68 million to $1.51 million at 7% (primary estimate $1.07 million) and from $0.66 million to $1.53 million at 3% (primary estimate $1.07 million). The rule also identifies one-time industry costs to read the rule and revise labeling.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2026-05267 — Reef Fish Fishery of the Gulf of America; Shallow-Water Grouper Management Measures
The Gulf of America is planning new rules to protect shallow-water groupers like scamp and yellowmouth by lowering catch limits and setting a fixed closed season for recreational fishing. These changes affect both recreational and commercial fishers and aim to keep grouper populations healthy while more long-term plans are developed. Comments on the proposal are open until April 17, 2026, so now’s the time to speak up!
Next: 2026-05322 — Effective Date of Requirement for Premarket Approval Applications for Blood Irradiators Intended To Prevent Metastasis
The FDA is planning to require companies that make blood irradiators used during cancer surgeries to get special approval before selling them. This change helps make sure these devices are safe and effective in preventing cancer spread. If finalized, manufacturers will have about 30 months to submit their approval applications, so they should get ready soon!